748 related articles for article (PubMed ID: 12439642)
41. Long-Term Effects of Enzyme Replacement Therapy for Anderson-Fabry Disease.
Tsujiuchi M; Ebato M; Maezawa H; Mizukami T; Nogi A; Ikeda N; Iso Y; Suzuki H
Int Heart J; 2019 Jan; 60(1):208-214. PubMed ID: 30464119
[TBL] [Abstract][Full Text] [Related]
42. Fabry disease: overall effects of agalsidase alfa treatment.
Beck M; Ricci R; Widmer U; Dehout F; de Lorenzo AG; Kampmann C; Linhart A; Sunder-Plassmann G; Houge G; Ramaswami U; Gal A; Mehta A
Eur J Clin Invest; 2004 Dec; 34(12):838-44. PubMed ID: 15606727
[TBL] [Abstract][Full Text] [Related]
43. Cardiac challenges in patients with Fabry disease.
Weidemann F; Linhart A; Monserrat L; Strotmann J
Int J Cardiol; 2010 May; 141(1):3-10. PubMed ID: 19720409
[TBL] [Abstract][Full Text] [Related]
44. Cardiac manifestations of Anderson-Fabry disease in heterozygous females.
Kampmann C; Baehner F; Whybra C; Martin C; Wiethoff CM; Ries M; Gal A; Beck M
J Am Coll Cardiol; 2002 Nov; 40(9):1668-74. PubMed ID: 12427421
[TBL] [Abstract][Full Text] [Related]
45. [Fabry disease: clinic and enzymatic diagnosis of homozygous and heterozygous. New therapeutic prospects].
Peces R; Olea T
Nefrologia; 2002; 22(6):540-6. PubMed ID: 12516287
[TBL] [Abstract][Full Text] [Related]
46. [Fabry disease in 2004].
Germain DP
Rev Prat; 2003 Dec; 53(20):2215-20. PubMed ID: 15018073
[TBL] [Abstract][Full Text] [Related]
47. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
[TBL] [Abstract][Full Text] [Related]
48. Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa.
Ramaswami U
Acta Paediatr; 2008 Apr; 97(457):38-40. PubMed ID: 18339186
[TBL] [Abstract][Full Text] [Related]
49. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.
Mehta A; Ricci R; Widmer U; Dehout F; Garcia de Lorenzo A; Kampmann C; Linhart A; Sunder-Plassmann G; Ries M; Beck M
Eur J Clin Invest; 2004 Mar; 34(3):236-42. PubMed ID: 15025684
[TBL] [Abstract][Full Text] [Related]
50. Fabry disease in patients with hypertrophic cardiomyopathy (HCM).
Beer G; Reinecke P; Gabbert HE; Hort W; Kuhn H
Z Kardiol; 2002 Dec; 91(12):992-1002. PubMed ID: 12490989
[TBL] [Abstract][Full Text] [Related]
51. Cardiac involvement in Fabry disease - A non-invasive assessment and the role of specific therapies.
Hongo K
Mol Genet Metab; 2022; 137(1-2):179-186. PubMed ID: 36088815
[TBL] [Abstract][Full Text] [Related]
52. Fabry disease and the heart.
Seydelmann N; Wanner C; Störk S; Ertl G; Weidemann F
Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):195-204. PubMed ID: 25987173
[TBL] [Abstract][Full Text] [Related]
53. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy.
Chimenti C; Pieroni M; Morgante E; Antuzzi D; Russo A; Russo MA; Maseri A; Frustaci A
Circulation; 2004 Aug; 110(9):1047-53. PubMed ID: 15313943
[TBL] [Abstract][Full Text] [Related]
54. Fabry disease--a primer for cardiologists.
Mursă A; Ginghină C; Jurcut R
Rom J Intern Med; 2014; 52(4):216-22. PubMed ID: 25726623
[TBL] [Abstract][Full Text] [Related]
55. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.
Pisani A; Spinelli L; Sabbatini M; Andreucci MV; Procaccini D; Abbaterusso C; Pasquali S; Savoldi S; Comotti C; Cianciaruso B
Am J Kidney Dis; 2005 Jul; 46(1):120-7. PubMed ID: 15983965
[TBL] [Abstract][Full Text] [Related]
56. [Cardiac manifestation of Fabry's disease: current knowledge].
Palecek T; Lubanda JC; Magage S; Karetová D; Bultas J; Linhart A
Vnitr Lek; 2004 Nov; 50(11):846-51. PubMed ID: 15648965
[TBL] [Abstract][Full Text] [Related]
57. Novel α-Galactosidase A Mutation (K391E) in a Young Woman With Severe Cardiac and Renal Manifestations of Fabry Disease.
Wakakuri H; Nakamura S; Utsumi K; Shimizu W; Yasutake M
Int Heart J; 2016 Sep; 57(5):637-9. PubMed ID: 27593536
[TBL] [Abstract][Full Text] [Related]
58. Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week.
Pieroni M; Moon JC; Arbustini E; Barriales-Villa R; Camporeale A; Vujkovac AC; Elliott PM; Hagege A; Kuusisto J; Linhart A; Nordbeck P; Olivotto I; Pietilä-Effati P; Namdar M
J Am Coll Cardiol; 2021 Feb; 77(7):922-936. PubMed ID: 33602475
[TBL] [Abstract][Full Text] [Related]
59. Fabry disease and cardiovascular involvement.
Anastasakis A; Papatheodorou E; Steriotis AK
Curr Pharm Des; 2013; 19(33):5997-6008. PubMed ID: 23448453
[TBL] [Abstract][Full Text] [Related]
60. Fabry disease.
Yuasa T; Takenaka T; Higuchi K; Uchiyama N; Horizoe Y; Cyaen H; Mizukami N; Takasaki K; Kisanuki A; Miyata M; Ohishi M
J Echocardiogr; 2017 Dec; 15(4):151-157. PubMed ID: 28674962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
